Biogen (MEX:BIIB) Receivables Turnover

: 1.14 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biogen's Revenue for the three months ended in Mar. 2023 was MXN44,396 Mil. Biogen's average Accounts Receivable for the three months ended in Mar. 2023 was MXN39,105 Mil. Hence, Biogen's Receivables Turnover for the three months ended in Mar. 2023 was 1.14.

Biogen Receivables Turnover Historical Data

The historical data trend for Biogen's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Receivables Turnover

5.60

5.68

5.76

5.21

4.84

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Receivables Turnover																1.25	1.29	1.26	1.22	1.14

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Receivables Turnover Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Biogen's Receivables Turnover falls in comparison to its industry or sector. The grey bar indicates the Receivables Turnover's extreme value range as defined by GuruFocus.

Biogen Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Biogen's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Receivables Turnover (A: Dec. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2022 )	/ (	(Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )
=	198340.607	/ (	(40242.314	+	41651.254)	/	2 )
=	198340.607	/	40946.784
=	4.84

Biogen's Receivables Turnover for the quarter that ended in Mar. 2023 is calculated as

	Receivables Turnover (Q: Mar. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2023 )	/ (	(Accounts Receivable (Q: Dec. 2022 )	+	Accounts Receivable (Q: Mar. 2023 ))	/	count )
=	44395.575	/ (	(41651.254	+	36558.305)	/	2 )
=	44395.575	/	39104.7795
=	1.14

Biogen (MEX:BIIB) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Biogen Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Biogen's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.